

For Diet Drug Recipient(s) Registered with the AHP Trust:

The circumstances which determine whether "Matrix A-1" or "Matrix B-1" is applicable are as follows:¹

1. Matrix A-1: Diet Drug Recipients who ingested Pondimin® and/or Redux™ for 61 or more days, who were diagnosed as FDA Positive, **whose conditions are eligible for matrix payments** but who do not have any condition or circumstance which makes Matrix B-1 applicable, receive payments on Matrix A-1.

2. Matrix B-1: Diet Drug Recipients **who are eligible for matrix payments** and to whom one or more of the following conditions apply, receive payments on Matrix B-1:

- For claims as to the mitral valve, Diet Drug Recipients who were diagnosed as having Mild Mitral Regurgitation (regardless of the duration of ingestion of Pondimin® and/or Redux™).
- Diet Drug Recipients who ingested Pondimin® and/or Redux™ for 60 days or less, who were diagnosed as FDA Positive.
- Diet Drug Recipients who ingested Pondimin® and/or Redux™ for 61 or more days, who were diagnosed as FDA Positive with any of the following conditions:

With respect to an aortic valve claim:

- The following congenital aortic valve abnormalities: unicuspid, bicuspid or quadricuspid valves, ventricular septal defect associated with aortic regurgitation;
- Aortic dissection involving the aortic root and/or aortic valve;
- Aortic sclerosis in people who are > 60 years old as of the time they are first diagnosed as FDA Positive; Aortic root dilatation >5.0 cm;
- Aortic stenosis with an aortic valve area <1.0 square centimeter by the Continuity Equation.

With respect to a mitral valve claim:

- The following congenital mitral valve abnormalities: parachute valve, cleft of the mitral valve associated with atrial septal defect;
- Mitral Valve Prolapse as determined by Echocardiogram. "Mitral Valve Prolapse" refers

¹ **Source:** Nationwide Class Action Settlement Agreement with American Home Products ("Fen-Phen Settlement Agreement") Section IV.B.2.d.(2)(c); *see also* Appendix to GREEN FORM.

to a condition where (a) the echoardiogram video tape or disk includes the parasternal long axis view and (b) that echocardiographic view shows displacement of one or both mitral leaflets >2mm above the atrial-ventricular border during systole, and >5mm leaflet thickening during diastole, as determined by a Board-Certified Cardiologist.

- Chordae tendineae rupture or papillary muscle rupture; or acute myocardial infarction associated with acute mitral regurgitation;
- Mitral annular calcification;
- M-Mode and 2-D Echocardiographic evidence of rheumatic mitral valves (doming of the anterior leaflet and/or anterior motion of the posterior leaflet and/or commissural fusion), except where there is no evidence of rheumatic valve disease upon pathological examination of mitral valve tissue.

With respect to claims for the aortic and/or mitral valve(s):

- Heart valve surgery prior to Pondimin® and/or Redux™ use on the valve that is the basis of claim;
- Bacterial endocarditis prior to Pondimin® and/or Redux™ use;
- FDA Positive regurgitation (confirmed by Echocardiogram) prior to Pondimin® and/or Redux™ use for the valve that is the basis of claim;
- Systemic Lupus Erythernatosus or Rheumatoid Arthritis¹ and valvular regurgitation and/or valvular abnormalities of a type associated with those conditions² ;
- Carcinoid tumor of a type associated with aortic and/or mitral valve lesions;
- History of daily use of methysergide or ergotamines for a continuous period of longer than 120 days.